Botanix Prescriptions Rise, But Sofdra Revenue Stalls As Cash Falls
Botanix Pharmaceuticals said Sofdra prescriptions shipped rose 5% from the previous quarter and gross sales increased, but net revenue remained flat at approximately $10 million, with a lower gross-to-net yield cited as a likely factor. Operating cash outflows fell 13% quarter-on-quarter, while cash on hand declined to approximately $24 million from approximately $37 million; Botanix has since initiated cost actions to preserve its cash runway.
Closing price · 2026-10-27: $0.011 · -15.38%